InclisiRan for Early Passivation of VulneRable AthEroSclerotic PlaqueS in Patients with Acute Coronary Syndromes（REPRESS）

"Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group."